Arbutus Biopharma Corp - Company Profile
Powered by 
All the sales intelligence you need on Arbutus Biopharma Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Arbutus Biopharma Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Arbutus Biopharma Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arbutus Biopharma Corp (Arbutus) is a clinical-stage biopharmaceutical company focused on infectious diseases. The company's main activities involve the development of therapeutics for the treatment of chronic hepatitis B virus (cHBV). Arbutus's major pipeline products include imdusiran (AB-729), an RNA interference (RNAi) therapeutic, and AB-101, an oral PD-L1 inhibitor. These products are designed to address unmet medical needs in the treatment of chronic hepatitis B virus (cHBV). Arbutus's therapeutics are primarily targeted at healthcare providers and patients dealing with chronic hepatitis B. The company relies on third-party manufacturers for the supply of its drug substances and products. The company operates in the US and Canada. Arbutus is headquartered in Warminster, Pennsylvania, the US.
Headquarters
Canada
Address
100-8900 Glenlyon Parkway, Warminster, British Columbia, V5J5J8
Website
www.arbutusbio.com
Telephone
1 267 4690914
No of Employees
19
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABUS (NASD)
Revenue (2024)
$14.1M
128.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
52.1%
(2024 vs 2023)
Market Cap*
$854.7M
Net Profit Margin (2024)
XYZ
79.0%
(2024 vs 2023)
* As of and is in US$
Arbutus Biopharma Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| AB-729 (RNA Interface): Hepatitis B |
| AB-101: Hepatitis B |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Others | In November, the company terminated clinical collaboration agreement with Antios Therapeutics, Inc. |
| 2021 | Contracts/Agreements | In December, the company and Qilu Pharmaceutical entered into an exclusive licensing agreement and strategic partnership to develop and Commercialize of AB-729 in China, Hong Kong, Macau and Taiwan. |
| 2021 | Contracts/Agreements | In July, the company and Vaccitech signed a clinical trial collaboration agreement for an RNAi therapeutic plus immunotherapeutic to treat patients with chronic hepatitis B virus (HBV) infection (CHB). |
Competitor Comparison
| Key Parameters | Arbutus Biopharma Corp | GSK plc | Gilead Sciences Inc | Mirum Pharmaceuticals Inc | Assembly Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United Kingdom | United States of America | United States of America | United States of America |
| City | Warminster | London | Foster City | Foster City | South San Francisco |
| State/Province | British Columbia | England | California | California | California |
| No. of Employees | 19 | 66,841 | 17,000 | 322 | 73 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lindsay Androski | Chairman; Chief Executive Officer; President | Executive Board | 2025 | 49 |
| Tuan Nguyen | Chief Financial Officer | Senior Management | 2025 | 50 |
| Andrew J. Sung | General Counsel | Senior Management | 2025 | - |
| Robert Alan Beardsley | Director | Non Executive Board | 2025 | 65 |
| Joseph Bishop | Director | Non Executive Board | 2025 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer